Activation antigens during the proliferative and secretory phases of endometrium and early-pregnancy decidua.
BACKGROUND
Clarifying the normal distribution of activation antigens will contribute to database construction studies of monoclonal-antibody-based therapies in endometrial disorders.


METHODS
In this study, endometrial tissue samples obtained during proliferative and secretory phases and decidual samples of early pregnancies were immunostained by the monoclonal antibodies anti-CD26, anti-CD30, anti-CD70, anti-CD71, and anti-CD98 using the indirect immunoperoxidase method.


RESULTS
CD26 is expressed on the glandular epithelium in the endometrium and decidua. Endothelial CD26 is expressed less in the decidua when compared to the endometrium. CD30 is strongly expressed by decidual cells. It is only weakly expressed on endometrial and decidual vessels. Glandular and endothelial CD70 expression is mainly seen in the proliferative phase of the menstrual cycle. Glandular CD71 expression is less in the decidua when compared to the endometrium. Its expression on stromal cells is more in the secretory phase of the menstrual cycle and in early pregnancy deciduae. It is expressed on endometrial vessels but not on decidual vessels. Glandular CD98 is expressed more in the decidua when compared to the endometrium. This antigen exists on endometrial lymphocytes. It is strongly expressed on the endothelium in the endometrium and decidua.


CONCLUSIONS
It seems that CD26 and CD70 are not involved in the functions of endometrial and decidual stromal cells. CD30 and CD71 are thought to be involved in decidualization. Absence of activation antigens other than CD98 on lymphocytes indicated an antigenic profile for large granular lymphocytes that is different from regular lymphocytes.
Ugur
Yesim
Y
Department of Histology-Embryology, Hacettepe University Medical Faculty, Ankara, Turkey. yesimulutas67@yahoo.com
Cakar
A Nur
AN
Beksac
M Sinan
MS
Dagdeviren
Attila
A
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015703:Antigens, CD / Q000032:analysis* / Q000276:immunology; D053282:CD27 Ligand / Q000032:analysis / Q000276:immunology; D003656:Decidua / Q000276:immunology* / Q000502:physiology; D018819:Dipeptidyl Peptidase 4 / Q000032:analysis / Q000276:immunology; D004717:Endometrium / Q000276:immunology* / Q000502:physiology; D005260:Female; D027261:Fusion Regulatory Protein-1 / Q000032:analysis / Q000276:immunology; D006801:Humans; D007124:Immunoenzyme Techniques; D007155:Immunologic Factors / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000032:analysis / Q000276:immunology; D008597:Menstrual Cycle / Q000276:immunology / Q000378:metabolism; D011247:Pregnancy; D011261:Pregnancy Trimester, First / Q000276:immunology / Q000378:metabolism; D011990:Receptors, Transferrin / Q000032:analysis / Q000276:immunology; D014591:Uterine Diseases / Q000628:therapy*
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D053282:CD27 Ligand; C068126:CD71 antigen; D027261:Fusion Regulatory Protein-1; D007155:Immunologic Factors; D017730:Ki-1 Antigen; D011990:Receptors, Transferrin; D018819:Dipeptidyl Peptidase 4